HEAMGEN, Inc. – a spin out of Giostar Inc. – has developed a patented, disruptive technology to manufacture O-negative Red Blood Cells (RBCs) from Stem Cells. This technology will ensure the blood supply chain resiliency in that blood and blood products remain safe and available for patients, both in the military community and the civilian medical sphere, especially in terms of sourcing, storage and distribution.
Blood products are deemed a
Critical Infrastructure Key Resource.
The present Coronavirus Pandemic of 2020 has revealed the even more acute need for donor independent methods of providing blood during times of crisis.
Impact: Coronavirus Pandemic
The World Health Organization (WHO) published the first detailed analysis on the global supply and demand for blood in October 2019 and found that 119 out of 195 countries do NOT have enough blood in their blood banks to meet hospital needs missing roughly 102,359,632 units of blood.
The world was lacking 30 million units of blood, and in the 119 countries with insufficient supply, that shortfall reached 100 million units.
China is the world’s second largest market for blood therapies reaching more than $6.2B in 2019.
“In a radiological or nuclear emergency, impacted communities will face a significant blood product shortage,” explained (former) BARDA Director Rick Bright, Ph.D.
“We are exploring donor-independent technology to increase surge capacity within the blood industry. Our nation must find innovative ways to make essential blood products available to save lives in any type of mass casualty incident.”
Current Complex Blood SupplyChain
HEAMGEN, Inc. has developed a patented, disruptive technology which simplifies the current blood supply chain to ensure supply chain resiliency in that blood and blood products remain safe and available for patients, both in the military community and the civilian medical sphere, especially in terms of sourcing, storage and distribution. Coronavirus interrupted RECRUITING as well as the Collection/Processing segment (Above Current Blood Supply Chain Diagram) due to the risk of contracting COVID-19.
Building Resiliency for the
Global Blood Supply Chain
THE HEAMGEN ADVANTAGES
Red Blood Cell manufacturing plants will be constructed globally to ensure abundant, safe supply of red blood cells
We manufacture safe Red Blood Cells, not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis
Our Red Blood Cells are O negative (Universal Donor) to eliminate incompatibility and allosensitization reactions
Trauma situations often do not allow for adequate blood typing due to time restrictions, so our red blood cells address that need effectively
Giostar USA | HEAMGEN Inc.
4660 La Jolla Village Drive
San Diego, CA 92122, USA